On October 11, 2018, Sharma, Amit; Lee, Min-Goo; Shi, Hu; Won, Miae; Arambula, Jonathan F.; Sessler, Jonathan L.; Lee, Jin Yong; Chi, Sung-Gil; Kim, Jong Seung published an article.Application In Synthesis of (6-Bromohexyl)triphenylphosphonium bromide The title of the article was Overcoming Drug Resistance by Targeting Cancer Bioenergetics with an Activatable Prodrug. And the article contained the following:
Nearly without exception, all known cancer chemotherapeutics elicit a resistance response over time. The resulting resistance is correlated with poor clin. outcomes. Here, we report an approach to overcoming resistance through reprogramming oncogene-directed alterations in mitochondrial metabolism before drug activation while simultaneously circumventing drug efflux pumps. Conjugate C1 increases cancer cell apoptosis and inhibits regrowth of drug-resistant tumors, as inferred from efficacy studies carried out in human cancer cells and in Dox-resistant xenograft tumor models. It also displays minimal whole-animal toxicity. These benefits are ascribed to an ability to evade chemoresistance by switching cancer cell metabolism back to normal mitochondrial oxidative phosphorylation while helping target the active Dox to first the mitochondrion and then the nucleus. The experimental process involved the reaction of (6-Bromohexyl)triphenylphosphonium bromide(cas: 83152-22-1).Application In Synthesis of (6-Bromohexyl)triphenylphosphonium bromide
The Article related to cancer doxorubicin drug resistance bioenergetics, Placeholder for records without volume info and other aspects.Application In Synthesis of (6-Bromohexyl)triphenylphosphonium bromide
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary